SELECT-AXIS 2: RCT UPA 15 mgQD vs. PBO in NRAxSpA as expected: ↘️disease activity ↘️pain and function ↘️QoL at 14 wks no new safety alerts https://t.co/2efpx7Mi6i

AxSpA and AxPsA 2 sides of the same coin or 2 different diseases? Divergent IL-23i efficacy data seem to suggest the latest. German GESPIC AxPsA cohort: *More frequently 🚺 *Less frequently B27+ *20% isolated Ax involvement @Rheumnow OP0026 #EULAR2022 https://t.co/FZP9nEyG7J

Phase 3 RCT upadacitinib in nrAxSpA. Clinical (ASAS40), PRO, and radiologic response seen at week 14 vs placebo @RheumNow #EULAR2022 OP0016 https://t.co/s3Vf4QiiAD https://t.co/gzlxZ3sxHF

• EULAR Abstract Archive

#EULAR2022 OP0073: Gender-specific assessment for MRI imaging criteria ⭐️Sex differences in axSpA - disease presentations, jt biomechanics, diagnostic delay in ♀️ ⭐️Higher fat metaplasia in ♂️, Sclerosis in ♀️ ⭐️Ankylosis much higher in ♂️ (DOR 40!) @Rheumnow

Hellamand et al. Sex differences in first TNFi response in AxSpA. Treatment efficacy (RR 0.85) and retention (58% vs 72% month 24) rates lower in females. @RheumNow #EULAR2022 OP0020 https://t.co/2IL88K7q40 https://t.co/hSJds5EJFK

• EULAR Abstract Archive

Bimekizumab (dual 17A/17F inhibitor) RCT in AS. ASAS40 45% vs 23% at week 16. All secondary clinical and imaging endpoints also + @RheumNow #EULAR2022 OP0019 https://t.co/RiZ7Divap3 https://t.co/ushogL5TaX

• EULAR Abstract Archive

Dr Fabian Proft @ProftDr present CONSUL open label RCT of effect of adding NSAIDS to TNFi on structural outcomes. Bottom line, no significant difference in mSASSS. However new syndesmophytes in 11% vs 25%. @RheumNow #EULAR2022 OP0018 https://t.co/OcYH6oKbJQ https://t.co/kxH5vUdibe

• EULAR Abstract Archive

Bimekizumab (dual IL-17F and IL-17A inhibitor) phase 3 study for treatment of active ankylosing spondylitis demonstrated ASAS40 improvement at wk 14 (44% vs. 25%). #EULAR2022 @RheumNow #ABSTOP0019 https://t.co/eohvNFG3GS

10 year study showed NSAIDs associated with slowing radiographic progression in axSpA patients. mSASSS progression numerically lower in COX2i pts compared to non-selective NSAIDs. @RheumNow #EULAR2022 #ABSTOP0021 https://t.co/dfz3rseikl

Secukinumab 300mg at week 52 in ankylosing spondylitis patients (who did not achieve inactive disease with SEC 150mg at week 16) experienced similar clinical response and safety profile regardless of dose escalation. #EULAR2022 @RheumNow #ABSTOP0023 https://t.co/7LeZMMWeRC